Jessica L.F. Teh

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

A Preexisting Rare <i>PIK3CA</i> E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <i>NRAS</i> Melanoma and Is Dependent on S6K1 Signaling

Gabriele Romano, Pei-Ling Chen, Ping Song et al. · Cancer Discovery · 2018 · 93 citations · Full text

Medicine, Cancer Biology, Oncology +17

<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

Jessica L.F. Teh, Phil F. Cheng, Timothy J. Purwin et al. · Cancer Discovery · 2018 · 77 citations · Full text

Medicine, Oncology, Pharmacology +16

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

Vivian Chua, Marlana Orloff, Jessica L.F. Teh et al. · EMBO Molecular Medicine · 2019 · 56 citations · Full text

Medicine, Cancer Biology, Oncology +17

Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

Daniel Gerlach, Michael Gmachl, Jürgen Ramharter et al. · Cancer Research · 2020 · 48 citations

Medicine, Oncology, Pharmacology +16